|
|
|
|
Science Sparks @ ACTREC
|
 05 th October 2026 |
Vol. No. 15 ; Issue No.755 |
|
|
Publications
|
|
1. Varma S, Dharne M, Moudgil A, Nair P, Ghate N, Santra M, Chaudhari P, Alam S, Awathare P, Chaudhari B (2026). A bioanalytical platform for dual-modal computed tomography and photoacoustic imaging using poly-γ-glutamic acid functionalized gold nanorods. Microchemical Journal
2. Patel MS, Janopaul-Naylor J, Ting FIL, Wu JF, McBride SM, Rathkopf DE, Feliciano EJG, Truong H, Iyengar P, Willmann J, Gorovets DE, Nguyen PL, Murthy V, Mahal BA, Lee NY, Nagar H, Dee EC (2026). Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer. Prostate Cancer and Prostatic Diseases.
Book Chapter
Tembhare, PR, Deshpande N, Ghogale S. (2027). Measurable Residual Disease. In: Biancotto, A., Dagur PK (Eds) Immunophenotyping. Methods in Molecular Biology, vol 3087. Humana, New York
Theses
1. Akhila George. 2026. Deciphering the Dynamics of Inflammasome Innate Immune Pathway in Oral Cancer (LIFE09202104027) (Guide: Dr Jyoti Kode)
2. Vaishnavee Anil Chikhale. 2026. Studies of Protein-Protein Interactions by Targeting the Mutations in Mitogen- Activated Protein Kinase (MAPK) Signalling Pathway, (LIFE09201904007) (Guide: Dr Ashok Varma)
|
|
|
|
|
|
|
Video of the Week
|
|
| Breaking Barriers: The Future of Prostate Cancer Care
|
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1941, Charles Huggins discovered that hormonal manipulation could cause prostate tumors to regress.
|
|
|
|
Cancer News
|
| |
|
Cancer stem cells have an “energy addiction” scientists may be able to exploit.
|
|
Sciencedaily, 02/10/2026
|
|
High-risk MDS stem cells appear to have an unexpected “energy addiction,” relying far more heavily than healthy blood-forming cells on a molecule called NAD. Disrupting this energy pathway selectively weakened the cancer-driving cells, revealing a potential new target for treatment...
|
| |
|
Can pancreatic cancer be stopped in its tracks? Radical tactic raises hopes.
|
|
Nature, 01/10/2026
|
|
In this approach, tissues that are growing abnormally are treated to keep them from turning cancerous and spreading. Interception is already being trialled for breast and skin cancers, among others. But now the success of a new drug that quashes pancreatic tumours is raising scientists’ hopes...
|
|
|
|
|
| |
|
|
|
Nuclear enzyme discovery unlocks new paths to combat breast cancer.
|
|
News-Medical, 01/10/2026
|
|
The data suggest the possibility of utilizing nuclear FAH as a biomarker of resistance to CDK4/6 inhibitors. Notably, this insight suggests CDK9-inhibition or combination therapy with CDK4/6-inhibitors could be an immediate, actionable clinical approach for mitigating relapse...
|
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
